Dr. Steven A. Fischkoff on Access to TIL Treatment for Patients With Melanoma

March 14, 2016
Steven A. Fischkoff, MD

Fischkoff says the goal of Lion Biotechnologies is to utilize a central manufacturing facility where medical professionals can submit tumor samples of their patients, and received the proper TIL-based treatment back from the manufacturing facility.

Steven A. Fischkoff, MD, chief medical officer, Lion Biotechnologies, Inc., discusses the future use of tumor infiltrating lymphocytes (TILs) in the treatment of melanoma. Fischkoff says the goal of Lion Biotechnologies is to utilize a central manufacturing facility where medical professionals can submit tumor samples of their patients, and received the proper TIL-based treatment back from the manufacturing facility.

Fischkoff says that while TILs have been researched in numerous amounts of cancers, the most advanced and concrete research has come from the melanoma field, specifically metastatic malignant melanoma. He adds that in trials where patients with melanoma have been treated with TIL-based treatments, response rates have been consistently "around 40% and even as high as 50%."